Isotretinoin is the go-to prescription for treatment of acne vulgaris, but ocular morbidities like dry eye disease and blepharoconjunctivitis are common due to the drug’s shrinking of oil glands. Patients and dermatologists may not be aware of these side effects or their prevalence. Faculty will look at clinical studies and discuss the best methods to counteract ocular adverse events, so that patients and practitioners alike will see the big picture.

Facial redness, bumps, flushing—it may seem that rosacea is all out in the open. But in this session Faculty will examine the less noticed, the conditions dermatologists often miss in their diagnoses. Neurogenic rosacea, rosacea fulminans, and rosacea blepharitis will be discussed, as well as other comorbidities.

Sponsored by Arcutis Biotherapeutics, Inc.

Clearing up any misconceptions, Faculty will look at the latest findings regarding topical and oral treatments for the two most common and chronic skin conditions. Which treatments are looking best in 2025? What advances have been made? Can both oral and topical treatments be used together, harmoniously, or is utopia far off?

An expert-led Q&A and panel discussion focused on acne and rosacea

Supported by an educational grant from Arcutis Biotherapeutics, Inc.

Seborrheic dermatitis (SD) is one of the most prevalent chronic inflammatory skin diseases, yet it continues to be widely misunderstood and inadequately managed in clinical practice. Historically considered a fungal disorder driven by Malassezia overgrowth, SD is now recognized as an immune-mediated, multifactorial condition shaped by barrier dysfunction, sebaceous activity, microbiome imbalance, and inflammatory dysregulation, which may be best addressed by recent therapeutic advances. Despite these insights, outdated perceptions persist, leading to overreliance on antifungals and corticosteroids, inadequate long-term control, and insufficient attention to the psychosocial burden that significantly impairs patients’ quality of life (QoL). The proposed session will leverage an interactive “MythBusters” format, directly addressing entrenched misconceptions by contrasting myths with evidence-based facts. By dispelling persistent myths, highlighting novel anti-inflammatory and barrier-supportive therapies, and emphasizing patient-centered strategies, this session will equip dermatology professionals to deliver more effective, durable, and holistic SD care, ultimately improving both clinical and quality-of-life outcomes for patients.

Neuromodulators are botulinum toxin injections used to treat wrinkles—you may know them by their popular names. We will discuss what’s new, what’s old, what’s FDA approved, what’s off label, and what’s best for particular cosmetic needs.

Treating skin of color with energy-based modalities comes with unique challenges, notably increased risk of scarring and post-inflammatory hyperpigmentation. Unfamiliarity with proper technique remains common. This session will clear up misconceptions by discussing how to select the proper tools, wavelengths, and procedures to treat patients of color.

Sponsored by Eli Lilly and Company.

Oral tranexamic acid, originally used to lessen menstrual bleeding, has shown efficacy in reducing hyperpigmentation disorders. Faculty will examine the clinical evidence behind this treatment and discuss who might be best suited for this approach. Future studies and current limitations will be considered.

An expert-led Q&A and panel discussion focused on cosmetic dermatology and laser treatments

Supported by an educational grant from Takeda Pharmaceuticals, U.S.A.

Sponsored by Regeneron (libtayo).

Patients with psoriasis may be up to 50% more likely to develop cardiovascular (CV) disease than patients without. A holistic approach to treatment that includes routine CV screening and risk assessment is necessary. Faculty will explain how inflammation leads to heart attack and stroke, examine recent studies, and consider whether managing one lowers the risk of the other.

An expert-led Q&A and panel discussion exploring psoriasis

Sponsored by Pfizer.

Beauty is more than skin deep—it affects our self-confidence and mental health. Skin conditions like eczema and psoriasis react to emotional states. This session holds the mirror up to psychodermatological disorders to get a clear picture of the skin/mind connection.

An increasing amount of research suggests a significant link between the skin and gut, both large microbiomes. In addition, inflammation affects joint health. Faculty will examine how all three are connected.

Sponsored by Eli Lilly and Company.

Obesity is a systemic disease that involves multiple organs, including the skin. Around 60-70% of obese patients present with dermatological changes. These commonly include skin tags, psoriasis, hidradenitis suppurativa, atopic dermatitis, and increased risk of skin infections. Anti-obesity medications may also cause adverse skin reactions. Practitioners will learn how to navigate this complicated, multi-faceted condition.

An expert-led Q&A and panel discussion exploring interdisciplinary approaches in dermatology

Just a freckle? Melanoma has a 99% 5-year survival rate if caught in its earliest stage (also called melanoma in situ). Practitioners will learn how to successfully identify melanoma, when to recommend screening in patients, and how to treat this relatively common cancer—at any stage.

Mohs surgery is the removal of skin layer by layer until there is no indication of cancer. Often the best treatment for certain basal- and squamous-cell carcinomas, it is also cost-effective and efficient. Faculty will illustrate best surgical practices and discuss when to recommend this treatment.

Sponsored by Pfizer.

Dermatological toxicities are those caused by cancer treatments—such as chemo and immunotherapies—and include hair loss, rash, and pruritis. Though rarely fatal, skin toxicities have profound effects on quality of life and mental well-being, and may lead to stopping or changing cancer treatment. An overview of common skin toxicities will be given and best treatment strategies will be compared.

An expert-led Q&A and panel discussion focused on dermatologic surgery and skin cancer care

Pollution, allergens, bacteria, sun—all the things our skin acts as barrier to in turn affects our skin, giving rise to various atopic conditions. Faculty will discuss environmental exposures and their link to skin disorders. Various treatment regimens be examined.

Faculty will review the four main pathologies of itch. Due to limited effective medications on the market, novel treatments and new clinical trials will be surveyed to ascertain whether any herald a revelation.

This session is aimed at pediatricians and primary-care physicians, often the first healthcare workers to see young patients. Common causes of rash will be discussed. Treatments for eczema, a chronic skin condition that affects up to 20% of children in the US, will be reviewed. Faculty will advise how to mitigate quality of life issues by taking a multidisciplinary approach to care.

An expert-led Q&A and panel discussion focused on itch and atopic dermatitis management

Bacterial, viral, fungal—no matter the pathogen, cutaneous infections are common, but vary widely by location, age, and socioeconomic status. In this session, faculty will provide an overview of some of the most prevalent skin infections, including how to diagnose, how to treat, and what advances practitioners can expect in the near future.

This is a close-up look of how immune responses in the skin, while essential for host defense, can drive inflammation and disease when dysregulated. Faculty will provide an overview of the cellular and molecular components of skin immunology and their context within disorders like eczema, psoriasis, and acne.

An expert-led Q&A and panel discussion exploring key updates within dermatology

Sponsored by Eli Lilly and Company.

Though topicals are often the first-line treatment in psoriasis, other treatments, like phototherapy, may be the more appropriate choice for patients with certain comorbidities and quality of life worries. The latest topical and phototherapy treatments will be discussed, and tips for improved patient adherence will be shared.

For patients with bullous disease, what is usually a minor annoyance—a blister—can be life-threatening due to increased risk of infection and dehydration. Faculty will discuss the top five causes of blisters for adult and pediatric patients. Common treatment options, and their adverse effects, will be examined.
https://pmc.ncbi.nlm.nih.gov/articles/PMC7388362/

An expert-led Q&A and panel discussion exploring psoriasis and bullous diseases

Sponsored by Arcutis Biotherapeutics, Inc.

This session will equip APPs with a structured approach to evaluating hair loss, not only a common concern but one with significant psychosocial impact. Faculty will review key elements of the clinical workup, including detailed history-taking, scalp examination, trichoscopic findings, and targeted laboratory tests. With a cool-head and analytical approach, practitioners can ease patient anxiety and begin to address the underlying cause of hair loss.

About half of patients with vitiligo receive no treatment despite the autoimmune disorder’s high psychosocial burden. Topical treatments often have low adherence rates and patients may not be aware of other options. Faculty will review the latest treatment advances, highlight scenarios where reassurance and education are appropriate, and discuss when specialist referral might be needed.
https://www.tandfonline.com/doi/10.1080/09546634.2024.2311793?url_ver=Z…

An expert-led Q&A and panel discussion navigating hair loss and vitiligo

This session will draw from real cases to study the nuances of difficult conversations in cosmetic dermatology, where the line between patient desire and medical necessity is not always clear. Faculty will examine strategies for navigating emotionally charged consultations with an emphasis on emotional intelligence, mutual respect, and building trust with the patient.

Image recognition software and predictive analytics are just two ways AI is changing dermatology. But as with all tools, one must know how to wield them. Faculty will weigh the pros and cons of integrating AI into daily practice. The challenges, or benefits, of diagnosing via telehealth services will also be considered.

An expert-led Q&A and panel discussion diving into cosmetic and modern tech in dermatology